“Breast cancer was the furthest thing from my mind,” Jacob Johnson tells PEOPLE ...

Where a woman lives significantly affects whether her breast cancer is diagnosed at an early or late stage, according to a national analysis published in the Journal of the American College of ...

A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature ...

The treatment landscape for breast cancer is shifting rapidly, driven by the rise of antibody-drug conjugates (ADCs), a class of treatments that are designed to deliver potent che ...

Data show T-DXd improves invasive disease-free survival and reduces the risk of distant recurrence in early HER2-positive breast cancer.

FDA Priority Review was granted for trastuzumab deruxtecan in post-neoadjuvant HER2-positive early breast cancer with residual invasive disease, with a regulatory decision anticipated in Q3 2026.

Priority review and Project Orbis evaluation advance potential post-neoadjuvant use of trastuzumab deruxtecan for high-risk HER2-positive early breast cancer with residual disease after neoadjuvant ...

A study that evaluated over 4000 patients with breast cancer found that, with a median follow-up of 18 years, history of ...

Arm lymphedema was reported in 13% of patients in the experimental group and 12% in the control group. Survival and safety outcomes were also similar with both regimens, study researchers reported.